AI for Brainwaves: New Partnership Aims to Revolutionize Seizure Detection

COLORADO SPRINGS, Colo. – April 22, 2026 – A new strategic partnership is set to bring the power of large-scale artificial intelligence to the front lines of neurological critical care. IntraNerve Neuroscience, a national provider of remote brain monitoring services, announced today it is collaborating with neuro-AI startup Piramidal to develop an “AI co-pilot” designed to dramatically accelerate the analysis of electroencephalogram (EEG) data.

The collaboration aims to tackle a fundamental challenge in neurology: the time-consuming and labor-intensive process of manually reviewing hours of complex brainwave activity to detect life-threatening events like seizures or strokes. By leveraging AI, the partners hope to shrink a process that takes hours into mere seconds, enabling faster clinical intervention and potentially improving patient outcomes.

The Technological Leap: From Text to Brainwaves

At the heart of the initiative is Piramidal, a New York-based startup founded in 2023. The company is developing what it calls a “foundation model for brain activity,” drawing an analogy to the Large Language Models (LLMs) like GPT that are trained on vast amounts of text. Piramidal’s model, by contrast, is being trained on a massive and diverse corpus of EEG recordings, teaching it to understand the complex “language” of the brain.

This foundational approach is designed to create a versatile and adaptable AI that can recognize patterns across a wide variety of patients, conditions, and medical devices. The ultimate goal is to create a tool that can instantly flag abnormalities for human review. According to the company, its AI can scan a full 24 hours of EEG data in seconds.

“Our model can scan a day's worth of EEG data within seconds, which is especially critical when monitoring large volumes of patients remotely,” said Dimitris Fotis Sakellariou, Co-Founder and CEO of Piramidal, in the announcement. “This partnership allows us to put this technology to work in the environment where it can have an immediate impact.”

The technology has already shown promise in research settings. In a retrospective pilot study with the Cleveland Clinic, another of Piramidal’s development partners, the system reportedly demonstrated approximately 90% sensitivity and 90% specificity for seizure detection. While still investigational, these results point to the potential for AI to significantly enhance diagnostic accuracy.

Bridging the Gap: AI in the Clinical Workflow

The partnership positions IntraNerve, with its two decades of experience in remote monitoring across more than 150 healthcare facilities, as the ideal proving ground for this technology. The collaboration is currently evaluating the AI in a real-world pilot to understand how it can be integrated into existing clinical workflows without causing disruption.

The vision is not to replace human experts but to augment them. The “AI co-pilot” will act as a powerful triage tool, continuously scanning patient data and alerting monitoring technologists to critical events. This allows highly trained clinicians to focus their attention where it is needed most, verifying the AI’s findings and making final diagnostic decisions.

“This partnership represents an important step in our efforts to explore how AI can improve the lives of our patients through analysis of complex neurological data,” stated Cheryll Poissant, IntraNerve’s Vice-President of EEG Services. “Our goal is expanding access, quality, and cost of care for EEG patients, which can be accomplished through Piramidal's industry leading expertise in AI and our decade plus experience of providing cEEG care across the country.”

This human-AI synergy is critical. Kris Pahuja, Co-Founder and CBO of Piramidal, emphasized the value of IntraNerve’s role. “IntraNerve's depth of experience in remote EEG monitoring makes them an ideal partner to help us understand how AI tools can integrate into real-world clinical workflows,” he said. “Their team brings the operational expertise and clinical rigor that's essential for translating this technology from research into practice.”

The Urgent Need in a Crowded Field

The push for AI in neurology is fueled by pressing healthcare challenges. A growing shortage of neurologists, particularly those with sub-specialty training in EEG interpretation, has created significant bottlenecks in care. Simultaneously, manual EEG analysis is not only slow but also prone to error, with some studies suggesting misinterpretation rates as high as 30%.

This partnership enters an emerging but competitive market for AI-powered neurodiagnostics. Companies like Natus Medical with its autoSCORE model and LVIS Corporation with its NeuroMatch platform are also developing AI tools to expedite EEG review. However, Piramidal aims to differentiate itself with its foundational model approach, which it claims is the largest ever trained on EEG data, designed for broader adaptability.

The potential market is substantial. By automating the initial review, AI tools could help alleviate the strain on specialists, reduce diagnostic delays, and expand access to high-quality neurological monitoring, especially in underserved hospitals without on-site experts.

Navigating the Path to Practice: Regulation and Ethics

Despite the technological promise, the road to widespread clinical adoption is paved with significant regulatory and ethical considerations. The AI models developed by Piramidal are currently for investigational use only and have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Gaining such approval for an AI/ML-based medical device is a rigorous process.

The FDA requires extensive evidence of a device's safety and effectiveness, often through the 510(k) pathway that requires showing “substantial equivalence” to an existing device. For novel technologies like a foundational brain model, the path may be more complex. As of early 2026, no device using generative AI or a large-scale foundation model has yet been authorized by the FDA, highlighting the evolving nature of regulatory oversight in this domain.

Beyond regulatory hurdles lie profound ethical questions. The use of massive patient datasets to train AI raises concerns about data privacy, security, and the potential for algorithmic bias. If training data is not sufficiently diverse, the AI could perform less accurately for certain demographic groups. Furthermore, ensuring transparency in how these complex “black box” algorithms arrive at a conclusion is critical for building trust among clinicians and patients.

Both IntraNerve and Piramidal acknowledge these challenges, rooting their long-term effort in a shared commitment to clinical excellence and patient safety. The success of their AI co-pilot will depend not only on its technical prowess but on its ability to navigate this complex landscape, proving it is a safe, reliable, and equitable tool that truly enhances human expertise in the critical moments of patient care.